Clinical Studies: Verifiable Performance by Design.
The ultimate measure of a diagnostic test is its performance in a real-world clinical setting. At reOpenTest, strong clinical study outcomes are not a goal we hope for, but a result we engineer from the start. Because our NomoFlow™ platform produces tests with unparalleled batch-to-batch consistency, the performance we validate in our labs is the same performance you can trust in yours. This is the cornerstone of verifiable reliability.
Featured Clinical Study
A Prospective, Multi-Center Evaluation of a Novel Rapid Antigen Combo Test for SARS-CoV-2, Influenza A/B, and RSV
This large-scale, prospective study across three clinical centers in the US and Europe demonstrated high PPA (Sensitivity) and NPA (Specificity) against the RT-PCR gold standard, with no significant performance variation between sites.
All Clinical Studies
Multi-Center Evaluation of the reOpenTest COVID-19/Flu A&B/RSV Antigen Combo Test
Demonstrated PPA of >95.5% and NPA of >99.1% for all four viral targets compared to RT-PCR across 1,254 symptomatic patients.
Go Deeper into the Data.
Our clinical specialists are available to walk you through our study methodologies, full data sets, and what they mean for your practice.